Business
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancerCRB-701 Phase 1 dose escalation underway in USA and Europe for patients with metastatic urothelial cancer and other nectin-4 enriched tumors and is on schedule for completion in Q4 2024Cash runway extended through Q3 2027 with $147 million of cash & investments at June 30, 2024 NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024. “We continue to make progress across our pipeline,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Updated clinical data was presented at ASCO 2024 by our development partner CSPC for CRB-701 (SYS6002). The data provided further evidence of the differentiated safety and encouraging efficacy first presented at ASCO GU in January 2024. This larger dataset of patients increases our confidence that CRB-701 is clinically active. The emerging safety data was reassuring showing low rates of skin rash and peripheral neuropathy and rare grade 3 adverse events. During the quarter, we commenced dose escalation in our corresponding U.S. and European Phase 1 clinical trial of CRB-701, a significant milestone that builds on this promising data. Separately, we expect to dose the first patient in Q1 2025 for CRB-913, our highly peripherally restricted oral CB1 inverse agonist. We look forward to continuing to advance our programs across our pipeline over the course of this year,” concluded Dr. Cohen. Key Corporate Updates CRB-701: Encouraging additional data from Phase 1 study presented at ASCO in June 2024: Results demonstrated 44% ORR and 78% DCR in metastatic urothelial cancer (“mUC”) and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/KgNo dose limiting toxicities (“DLTs”) have been observed to date in doses up to and including 4.5 mg/KgThree cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all were resolvedEarly pharmacokinetics (“PK”) data demonstrate consistently lower levels of free MMAE than enfortumab vedotin across all doses in the study, including 4.5 mg/Kg Dose escalation commenced...